Chong Kun Dang launches Camtobell injection, camptothecin analogue topoisomerase I inhibitor

Chong Kun Dang Pharmaceutical Co. said it launched Korea's 8th new drug Camtobell injection for the treatment of ovarian cancer (second-line therapy) and small-cell lung cancer (first-line therapy) on March 2, which was approved by Korea Food and Drug Administration in October of last year, as a result of its intensive 10-year research with an investment of 15.0 billion won.

Clinical studies...